On April 11, 2025, Entero Therapeutics, Inc. was notified by Nasdaq that it does not meet the minimum stockholders equity requirement for continued listing, reporting a negative equity of ($3,876,738) as of December 31, 2024, and must submit a compliance plan by May 26, 2025.